PDF下载 ( 1872 KB)
Application of nuclear receptor in pathogenesis research and drug development for nonalcoholic fatty liver disease
-
摘要:
非酒精性脂肪性肝病(NAFLD)是发达国家最常见的肝病,近年来在我国发病率呈现上升趋势,对社会卫生系统造成一定负担。NAFLD发生发展过程受到遗传和表观遗传、转录因子和激素、营养和环境等多重影响因素的相互作用。简要探讨了核受体在NAFLD发生机制中的研究进展,以加深对该疾病的理解和认识。
Abstract:Nonalcoholic fatty liver disease( NAFLD) is the most common type of liver disease in developed countries,and in recent years,the prevalence rate of NAFLD tends to increase in China,which brings heavy burden to the social health system. The development and progression of NAFLD are affected by the interaction between multiple influencing factors including genetic and epigenetic factors,transcription factors,hormones,nutrition,and environmental factors. This article reviews the research advances in the role of nuclear receptor in the pathogenesis of NAFLD,in order to deepen the understanding of this disease.
-
[1] ZHOU J,ZHOU F,WANG W,et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology,2020,71(5):1851-1864. [2] IP E,FARRELL GC,ROBERTSON G,et al. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice[J]. Hepatology,2003,38(1):123-132. [3] HARMON GS,LAM MT,GLASS CK. PPARs and lipid ligands in inflammation and metabolism[J]. Chem Rev,2011,111(10):6321-6340. [4] SINGARAVELU R,CHEN R,LYN RK,et al. Hepatitis C virus induced up-regulation of microRNA-27:A novel mechanism for hepatic steatosis[J]. Hepatology,2014,59(1):98-108. [5] HACZEYNI F,WANG H,BARN V,et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice[J]. Hepatol Commun,2017,1(7):663-674. [6] RATZIU V,HARRISON SA,FRANCQUE S,et al. Elafibranor,an agonist of the peroxisome proliferator-activated receptor-αand-δ，induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology,2016,150(5):1147-1159. e5. [7] PLOTON M,MAZUY C,GHEERAERT C,et al. The nuclear bile acid receptor FXR is a PKA-and FOXA2-sensitive activator of fasting hepatic gluconeogenesis[J]. J Hepatol,2018,69(5):1099-1109. [8] SINAL CJ,TOHKIN M,MIYATA M,et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis[J]. Cell,2000,102(6):731-744. [9] CARON S,HUAMAN SAMANEZ C,DEHONDT H,et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes[J]. Mol Cell Biol,2013,33(11):2202-2211. [10] SINGH AB,DONG B,KRAEMER FB,et al. Farnesoid X receptor activation by obeticholic acid elevates liver low-density lipoprotein receptor expression by mRNA stabilization and reduces plasma low-density lipoprotein cholesterol in mice[J]. Arterioscler Thromb Vasc Biol,2018,38(10):2448-2459. [11] YOUNOSSI ZM,RATZIU V,LOOMBA R,et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis:Interim analysis from a multicentre,randomised,placebo-controlled phase 3 trial[J]. Lancet,2019,394(10215):2184-2196. [12] TANGIRALA RK,BISCHOFF ED,JOSEPH SB,et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis[J]. Proc Natl Acad Sci U S A,2002,99(18):11896-11901. [13] HEGARTY BD,BOBARD A,HAINAULT I,et al. Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c[J]. Proc Natl Acad Sci U S A,2005,102(3):791-796. [14] RONG X,ALBERT CJ,HONG C,et al. LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition[J]. Cel Metab,2013,18(5):685-697. [15] ZHOU J,FEBBRAIO M,WADA T,et al. Hepatic fatty acid transporter Cd36 is a common target of LXR,PXR,and PPARgamma in promoting steatosis[J]. Gastroenterology,2008,134(2):556-567. [16] HE J,GAO J,XU M,et al. PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice[J].Diabetes,2013,62(6):1876-1887. [17] HAUGHTON EL,TUCKER SJ,MAREK CJ,et al. Pregnane X receptor activators inhibit human hepatic stel ate cell transdifferentiation in vitro[J]. Gastroenterology,2006,131(1):194-209. [18] REDDY AB,MAYWOOD ES,KARP NA,et al. Glucocorticoid signaling synchronizes the liver circadian transcriptome[J].Hepatology,2007,45(6):1478-1488. [19] MARINO JS,STECHSCHULTE LA,STEC DE,et al. Glucocorticoid receptorβinduces hepatic steatosis by augmenting inflammation and inhibition of the peroxisome proliferator-activated receptor(PPAR)α[J]. J Biol Chem,2016,291(50):25776-25788. [20] PATEL R,PATEL M,TSAI R,et al. LXRβis required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice[J]. J Clin Invest,2011,121(1):431-441. [21] WANG Y,VISCARRA J,KIM SJ,et al. Transcriptional regulation of hepatic lipogenesis[J]. Nat Rev Mol Cell Biol,2015,16(11):678-689. [22] le MARTELOT G,CLAUDEL T,GATFIELD D,et al. REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis[J]. PLo S Biol,2009,7(9):e1000181. [23] KIM EJ,YOON YS,HONG S,et al. Retinoic acid receptor-related orphan receptorα-induced activation of adenosine monophosphate-activated protein kinase results in attenuation of hepatic steatosis[J]. Hepatology,2012,55(5):1379-1388. [24] YANG JD,ABDELMALEK MF,PANG H,et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis[J]. Hepatology,2014,59(4):1406-1414. [25] CHOW JD,JONES ME,PRELLE K,et al. A selective estrogen receptorαagonist ameliorates hepatic steatosis in the male aromatase knockout mouse[J]. J Endocrinol,2011,210(3):323-334. [26] GROSSMANN M,WIERMAN ME,ANGUS P,et al. Reproductive endocrinology of nonalcoholic fatty liver disease[J]. Endocr Rev,2019,40(2):417-446. -
本文二维码
计量
- 文章访问数: 923
- HTML全文浏览量: 47
- PDF下载量: 296
- 被引次数: 0
下载:
